Brugia malayi (B. malayi)

Brugia malayi is a parasitic nematode and one of the primary causative agents of lymphatic filariasis, a neglected tropical disease characterized by severe lymphedema and elephantiasis. As a complex multicellular organism, it is not a single molecular target but a pathogen containing various enzymes and receptors that are targeted by anthelmintic therapies. The parasite is transmitted to humans through the bite of infected mosquitoes, after which the larvae migrate to the lymphatic vessels to mature into adult worms. Current therapeutic strategies focus on the use of microfilaricidal drugs like ivermectin and diethylcarbamazine to reduce transmission and alleviate symptoms. Additionally, albendazole is often used in mass drug administration programs to disrupt the parasite's life cycle. Some treatments also utilize doxycycline to target Wolbachia, an essential endosymbiotic bacterium required for the worm's survival and reproduction. Chronic infection is characterized by significant lymphatic damage and secondary bacterial infections, resulting in long-term disability. Understanding the molecular biology of Brugia malayi remains critical for developing new macrofilaricidal agents that can eliminate adult worms.

Other names

Malayan filariaFilarial worm

Ivermectin acts as an agonist at glutamate-gated chloride channels leading to parasite paralysis; diethylcarbamazine inhibits arachidonic acid metabolism and enhances host immune clearance; albendazole inhibits microtubule polymerization; doxycycline targets the essential Wolbachia endosymbiont within the parasite.